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Abstract
Background: Breast cancer is uncommon in young women and correlates with a less favourable prognosis; still it is the
most frequent cancer in women under 40, accounting for 30–40% of all incident female cancer. The aim of this study was to
study prognosis in young women, quantifying how much stage at diagnosis and management on the one hand, and
tumour biology on the other; each contribute to the worse prognosis seen in this age group.
Methodology/Principal Findings: In a registry based cohort of women aged 20–69 (n=22 017) with a primary diagnosis of
invasive breast cancer (1992–2005), women aged 20–34 (n=471), 35–39 (n=858) and 40–49 (n=4789) were compared with
women aged 50–69 years (n=15 899). The cumulative 5-year relative survival ratio and the relative excess mortality (RER)
were calculated. The cumulative 5-year relative survival ratio was lowest in women aged 20–34. The RER was 2.84 for
women aged 20–34 and decreased with increasing age (RER 1.76 and 1.17 for women aged 35–39 and 40–49, respectively).
The excess risk was, however, present only in disease stages I and II. For women aged 20–34 with stage I disease RER was
4.63, and 6.70 in the subgroup with tumour size 1–10 mm. The absolute difference in stage I between the youngest and the
reference groups amounted to nearly 8%, with a 90% 5-year survival in women aged 20–34. In stages IIa and IIb, the relative
excess risk was not as dramatic, but the absolute differences approached 15%. The youngest women with small tumours
generally received more aggressive treatment than women in older age groups.
Conclusions: After correction for stage, tumour characteristics and treatment, age remained an independent risk factor for
breast cancer death in women ,35 years of age. The excess risk for young women was only seen in early stages of disease
and was most pronounced in women with small tumours. Young women affected by breast cancer have a high risk of dying
compared to their middle-aged counterparts even if diagnosed early and receiving an intense treatment.
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Introduction
Approximately 7% of all breast cancers are diagnosed in women
,40 years of age and less than 4% in women below the age of 35
[1,2,3]. Although breast cancer is uncommon in young women, it
is the most frequent cancer in women ,40, accounting for
30–40% of all incident female cancer [4,5].
Young age at diagnosis influences prognosis negatively
[1,6,7,8,9,10]. This could partly be explained by young women
more often being diagnosed at advanced stages [1,11] and by
unfavourable tumour characteristics more often being present
[8,11,12,13,14,15]. It has not been quantified how much stage at
diagnosis and management on one hand, and tumour biology on
the other, each contribute to the poor prognosis.
At the other end of the age spectrum, breast cancer in elderly
women is also associated with an inferior prognosis when
compared to that of middle-aged women [6,16]. In a prior study
we focused on the elderly and found that less diagnostic activity
and less intensive treatment were major explanations for their
relatively low survival [17]. We interpreted our findings to be
partly due to less rigorous guidelines for the treatment of women
aged .70 and were alarmed that unclear guidelines might also
contribute to the worse prognosis seen in young women, since
guidelines for treating younger women have been less structured
than for middle-aged women.
The aim of the present study was to investigate to what degree a
worse prognosis in young women can be explained by stage,
tumour characteristics and treatment procedures.
Methods
2.1. Participants
Data were collected from the regional breast cancer registers in
two of Sweden’s six health-care regions (Stockholm/Gotland and
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3.9 million inhabitants, thus covering about 43% of the Swedish
population. The registers contain prospectively collected data on
patient and tumour characteristics, types of treatment and follow-
up. The registers are updated continuously by matching with the
National Population Register and the mandatory Swedish Cancer
Register to ensure a high coverage. The validity of the Swedish
Cancer Register has been tested previously and found to be very
high for the purpose of breast cancer studies [18,19].
A cohort of all women aged 20–69 with a primary diagnosis of
invasive breast cancer between 1992 and 2005 was followed until
the end of 2006. Of the original cohort, 22 017 women were
eligible after exclusion of 52 women with less than one month
follow-up. Women with bilateral disease at diagnosis were
included only once, with the most advanced cancer as the index
tumour. For women offered neoadjuvant treatment and those not
operated on, staging was based on clinical and preoperative biopsy
data. Data on tumour stage were based on the UICC criteria for
histopathological TNM stage [20]. The age interval was chosen to
allow comparison of young women with middle-aged women, as
the latter group is known to have the best survival [10,21,22,23].
The time interval was chosen to represent recent clinical practice
and registration procedures, i.e. with homogeneous treatment
guidelines and full coverage by regional breast cancer registers.
We chose the cut off at 50 years to define young women and
further divided them into three groups (20–34 years, 35–39 years
and 40–49 years) in accordance with earlier studies and current
treatment recommendations for women ,35 years [24]. Women
aged 50–69 years served as a comparison group.
All women aged 50–69 years were invited to screening
mammography every second year. For women aged 40–49 the
routines for screening mammography differed between the two
regions, implying that approximately 50% of women aged 40–49
were invited for mammography with an interval of 1.5 years, while
the other 50% were not.
2.2. Treatment
During the study period treatment for breast cancer was
performed according to regional and national guidelines that
closely follow international practice. Surgery involved either
modified radical mastectomy or breast conserving surgery [25],
combined with either a level I and II axillary clearance [26] or a
sentinel node biopsy [27].
Radiotherapy to the remaining breast parenchyma up to a total
dose of 50–54 Gy (Grey) was recommended as standard treatment
after breast conserving surgery. Since 2003 a boost of 10–16 Gy to
the tumour bed has been offered to women of 40–45 years.
Radiotherapy to the axilla in a dose of 46–54 Gy has been given to
women with involved axillary nodes (to all with $4 involved nodes
and to a majority with 1–3 involved nodes). After mastectomy a
total dose of 50–54 Gy has been given to the chest wall if the
tumour primarily invaded the pectoral muscle, if extensive
multifocality, when tumour size $50 mm or smaller if involved
axillary nodes.
During the early years of the study period, tamoxifen was not
routinely given to premenopausal women [28]. After 1994
tamoxifen was recommended to all women with hormone receptor
positive disease but in one of the two regions, only to women with
tumours larger than 10 mm. Since 2005 aromatase inhibitors have
been recommended postmenopausal women with node positive
disease.
Chemotherapy, mainly 5-fluorouracil, epirubicin, cyclophos-
phamide (FEC), was recommended to all women with node-
positive disease or node-negative, hormone receptor negative
disease. For node-positive breast cancer docetaxel in sequence
with anthracyclines was introduced in 2004.
2.3. Ethics
The regional breast cancer data bases used in this study have a
general ethic committee admittance from the regional ethics
committee at Karolinska Institutet (diary number 03–630) for
studies assessing given treatment and outcome based on the
retrospective data collected. The data are to be handled and
analyzed without possibility to identify individual patients, and no
written consents are thus requested. This retrospective study has
fully met the stated criteria and has thus been performed under the
above mentioned general admission.
2.4. Statistical Methods
The studied end-point was 5-year relative survival ratio (RSR).
The observation time was defined as the time between the date of
diagnosis and death. In the absence of event, the observation time
was censored at the date of end of follow up (31 December 2006).
The relative survival ratio was calculated by comparing the
observed survival of the women in the study population with the
expected survival of the general population matched with age, sex,
calendar period and county of residency [29]. The general
population in this study was represented by all females in the
Uppsala/O ¨ rebro and Stockholm/Gotland health-care regions
stratified by county (8 counties). Data for calculating county-
specific life-tables were collected from Statistics Sweden [30]. SAS
9.1 software was used for all statistical analyses.
The Fisher’s exact test was used to test the independence
between age and tumour and treatment variables (dichotomized
into extremes).
To study differences in survival between age groups while
adjusting for the confounding factors available in the dataset, i.e.,
stage (I, IIa, IIb, III, IV, and undefined owing to unknown lymph
node status or tumour size) and calendar period of diagnosis
(1992–93, 1994–95, 1996–97, 1998–99, 2000–01, 2002–03,
2004–05), we modelled excess mortality using Poisson regression
[31]. In addition, information was retrieved on tumour size
(1–10 mm, 11–20 mm, 21–50 mm, $51 mm, missing), lymph
node involvement (positive, negative, missing, 1–3 engaged lymph
nodes, $4 engaged lymph nodes), tumour grade (I, II, III,
missing), hormonal receptor status [estrogen and progesterone
(ER/PR); positive, negative, missing], multifocality (yes, missing),
surgical treatment [mastectomy, breast conservation (BCS), other
operation, none, missing] and prescribed oncological treatment
[neoadjuvant chemotherapy, chemotherapy, radiotherapy, endo-
crine therapy (ET)]. Stratification according to stage was also
performed in order to study whether the differences in survival
between age groups were consistent across levels of this variable.
We performed a multivariate analysis adjusted by year of
diagnosis, stage at diagnosis and oncological treatment (radiother-
apy, chemotherapy, ET), stratified on tumour characteristics to
evaluate the independent effect of age on survival. Furthermore,
we studied differences in survival between the age groups in stage
I-IIb while adjusting for the potential determinants by modeling
the excess mortality (RER) using Poisson regression. To assess the
effect of the different variables separately, as well as in addition to
each other, five separate models were made.
Results
3.1. Patient Characteristics
Tumour and treatment characteristics of the 22 017 women
included in the study are shown in Table 1. Compared with
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Age at diagnosis (years)
20–34 35–39 40–49 50–69
n=471 (2.1) n=858 (3.9) n=4789 (21.8) n=15899 (72.2)
Tumour size (mm)
1–10 64 (13.6) 129 (15.0) 876 (18.3) 4317 (27.2)
11–20 153 (32.5) 332 (38.7) 1965 (41.0) 6746 (42.4)
21–50 172 (36.5) 288 (33.6) 1441 (30.1) 3698 (23.3)
$51 35 (7.4) 57 (6.6) 206 (4.3) 470 (3.0)
Missing 47 (10.0) 52 (6.1) 301 (6.3) 668 (4.2)
Axillary lymph node status
Negative 234 (49.7) 410 (47.8) 2624 (54.8) 9661 (60.8)
Positive 205 (43.5) 412 (48.0) 1908 (39.8) 4818 (30.3)
1–3 pos nodes 118 (25.1) 263 (30.7) 1279 (26.7) 3279 (20.6)
$4 pos nodes 87 (18.5) 149 (17.4) 629 (13.1) 1539 (9.7)
Missing 32 (6.8) 36 (4.2) 257 (5.3) 1420 (8.9)
Tumour stage
I (T1+N0) 126 (26.8) 264 (30.8) 1836 (38.3) 7430 (46.7)
IIa (T1+N1 or T2+N0) 146 (31.0) 262 (30.5) 1395 (29.1) 4179 (26.3)
IIb (T2+N1 or T3+N0) 106 (22.5) 184 (21.5) 826 (17.2) 1877 (11.8)
III (T3+N1 or T4) 55 (11.7) 87 (10.1) 382 (8.0) 678 (4.3)
IV (M1) 15 (3.2) 25 (2.9) 95 (2.0) 271 (1.7)
Undefined 23 (4.9) 36 (4.2) 255 (5.3) 1464 (9.2)
Tumour grade
I 14 (3.0) 42 (4.9) 364 (7.6) 1850 (11.6)
II 38 (8.1) 134 (15.6) 862 (18.0) 3248 (20.4)
III 115 (24.4) 176 (20.5) 575 (12.0) 1610 (10.1)
Missing 304 (64.5) 506 (59.0) 2988 (62.4) 9191 (57.8)
Hormone receptor status
Positive* 219 (46.5) 517 (60.3) 3050 (63.7) 10148 (63.8)
Negative** 156 (33.1) 194 (22.6) 778 (16.2) 2565 (16.1)
Missing 96 (20.4) 147 (17.1) 961 (20.1) 3186 (20.0)
Multifocal tumour
Yes 81 (17.2) 196 (22.8) 788 (16.4) 2006 (12.6)
Missing 156 (33.1) 279 (32.5) 1706 (35.6) 5659 (35.6)
Surgical treatment
Breast Conservation (BCS) 211 (44.8) 413 (48.1) 2658 (55.5) 10151 (63.8)
Mastectomy 224 (47.6) 411 (47.9) 1914 (40.0) 5229 (32.9)
Other operation 3 (0.6) 8 (0.9) 42 (0.9) 81 (0.5)
None 31 (6.6) 26 (3.0) 157 (3.3) 382 (2.4)
Missing 2 (0.4) 0 18 (0.4) 56 (0.4)
Oncological therapy
Neoadjuvant treatment 61 (14.0) 111 (13.5) 387 (8.5) 662 (4.3)
Chemotherapy 307 (65.2) 522 (60.8) 2212 (46.2) 4209 (26.5)
Radiotherapy 335 (71.1) 637 (74.2) 3608 (75.3) 11999 (75.5)
If BCS also radiation 194 (91.9) 387 (93.7) 2486 (93.5) 9382 (92.4)
Endocrine therapy (ET) 192 (40.8) 416 (48.5) 2436 (50.9) 9659 (60.8)
If hormonal positive also ET 151 (69.0) 337 (65.2) 1975 (64.8) 7391 (72.8)
Distribution of patient-, tumour- and treatment characteristics of women aged 20–69 years diagnosed with primary breast cancer of all stages between 1992 and 2005
(22 017 women). Values are numbers (percentages). *ER positive, PR positive or negative, **ER and PR negative.
doi:10.1371/journal.pone.0007695.t001
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(49% were $21 mm vs. 27% in the older age group). Their
tumours were also more often multifocal (26% vs 20%), high grade
(69% vs 24% for grade III) and hormone receptor- negative (33%
vs 16%). Fewer women ,35 years presented with stage I disease
(27% vs 47%). Lymphatic involvement was more common in
women ,35 years (49% vs 34%) and they displayed a more
advanced lymph node status (42% vs 32% having $4 involved
lymph nodes).
3.2. Treatment
When comparing treatment regimes between women ,35 years
and women of 50–69 years, there were differences as expected
from the stage distribution: a larger proportion of women ,35
years were treated with mastectomy (48% vs 33%), chemotherapy
was more common in women ,35 years (65% vs 26%), and use of
endocrine therapy was not as common (41% vs 61%) as in the
older age group. There were no differences between the age
groups in either use of radiotherapy (71% vs 76%) or use of
endocrine therapy (in subjects with endocrine responsive tumours
69% vs 73%).
3.3. Survival
As of December 31 2006, 3723 (17%) women in our study
population had died, of whom 125 were in the age group 20–34
years (26% of all women aged 20–34), 173 aged 35–39 years
(20%), 757 aged 40–49 years (16%) and 2668 aged 50–69 years
(17%).
The cumulative 5-year relative survival ratio (RSR) was lowest
in women ,35 years and increased with age. There was a marked
distinction in relative excess mortality (RER) in women ,35 years
compared with older age groups in a model unadjusted for stage
(RER 2.84 in comparison with women aged 50–69). In the crude
analysis women of 35–49 years also had a worse prognosis
compared with the oldest group (Table 2). As expected from the
stage distribution in the different age groups, stage at diagnosis was
a major explanatory factor for these differences. The adjusted
analysis no longer showed a worse survival for the women aged
35–39, but the adjustment did not remove a higher RER for the
youngest women.
We further stratified the survival analyses by stage (I, IIa, IIb,
III+IV and undefined) to look at stage specific differences (Table 3).
Women ,35 years with stage I disease had a 4.63-fold excess risk
of dying within 5 years. When dividing stage I into tumour sizes
1–10 mm and 11–20 mm, the highest relative excess mortality was
seen in the two youngest age groups with the smallest tumours, i.e.
1–10 mm. The absolute difference in stage I between the youngest
and the reference groups amounted to nearly 8%, with a 90%
5-year survival in women aged 20–34. In stages IIa and IIb, the
relative excess risk was not as dramatic, but the absolute
differences approached 15%. In stage III and IV, the RER for
the younger women were actually lower than 1.0, but these
subgroups are small with limited statistical precision. Figure 1
illustrates the relationship further: the prognosis is generally good
in stage I, but there are clear differences between the age groups.
Prognosis rapidly becomes worse with stage, with more pro-
nounced absolute differences between the age groups up to and
including stage IIb.
As the excess risk was noted only in young women with the
earliest stages of disease (stages I, IIa and IIb), further analyses were
restricted to women in these stages. To elucidate the effect of age vs
treatment variables on survival, we performed a multivariate
analysis stratified on tumour characteristics, correcting for year,
stage at diagnosis and oncological treatment (Table 4). We found a
significant excess risk of mortality in the women ,35 years,
compared with the reference group of 50–69 years, in strata with
traditionally good prognostic signs such as small tumour size,
absence of lymphatic involvement and hormone receptor-positive
tumours. The worst relative survival was observed in the youngest
women with the smallest tumours. The general pattern was a worse
prognosis for women ,40 years in nearly all subgroups, but a
tendency for women aged 40–49 to do betterthan those aged 50–69
with the exception of the strata with tumours less than 20 mm.
We further addressed the question if the youngest women with
small tumours were under-treated, but found, as shown in Table 5,
that they generally received more aggressive treatment than
women in older age groups.
Finally, we undertook a series of multivariate analyses to
investigate the combined effect of all potential determinants
available in the dataset and to try to elucidate which of the
covariates contributed most to the differences (Table 6). In the
simplest model, women aged 20–34 years with stage I, IIa and IIb
disease had a markedly worse relative survival (RER 3.62) than
women aged 50–69 years. Inclusion of year of diagnosis (model 2)
Table 2. Cumulative 5-year relative survival ratio (RSR) and the estimated relative excess risks of mortality (RER) by age.
Total 5-years survival Crude
2,4 Adjusted
3,5
No Expected Observed RSR 95% CI RER 95% CI RER 95% CI
Age
20–34 471 99.8 74.7 74.8 70.1–78.9 2.84 2.31–3.49 1.63 1.32–2.01
35–39 858 99.7 83.8 84.1 81.2–86.6 1.76 1.45–2.14 1.08 0.89–1.32
40–49 4789 99.1 88.3 89.0 88.0–90.0 1.17 1.04–1.31 0.84 0.75–0.94
50–69 15899 96.8 87.8 90.7 90.1–91.2 1.00 (ref.) 1.00 (ref.)
The deviance is a measure of the models goodness-of-fit. Under the hypothesis that the model fits, the deviance should follow a chi-square distribution with the
specified degrees of freedom).
2Likelihood ratio test of the effect of age in the model; df=3, chi-square=96.7, p,0.0001.
3Model adjusted for year (1992–93, 1994–95, 1996–97, 1998–99, 2000–01, 2002–03, 2004–05) and stage (I, IIa, IIb, III, IV, undefined). Likelihood ratio test of the effect of
age in the model; df=3, chi-square=33.5, p,0.0001.
4Deviance 26, Residual df 12.
5Deviance 945, Residual df 760.
Cumulative 5-year relative survival ratio (RSR) and the estimated relative excess risks of mortality (RER) by age with 95% confidence intervals (CI) of women 20–69 years,
diagnosed with primary breast cancer of all stages between 1992 and 2005 (22 017 women).
doi:10.1371/journal.pone.0007695.t002
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lowered the RER to 2.35, indicating that stage at diagnosis is an
important explanatory variable. After the introduction of all
tumour characteristics, the RER dropped to 1.83 (model 4). The
final introduction of treatment (model 5) led to a minor shift in the
RER estimate to 1.76, thus indicating that tumour characteristics
rather that treatment activity is the most important explanatory
variable.
Discussion
Prognosis in breast cancer has improved dramatically over the
past decades, and this study underlines the very good prognosis
especially in early stages. As expected from earlier studies women
,35 years have a distinctly worse survival than middle-aged
women. This study also confirms that women aged 40–49 years
have the best survival [6,16,22,23]. Younger women present at a
later stage of disease, but that alone does not explain their worse
survival since they also have a worse prognosis stage by stage. The
distribution of tumour characteristics shown in this study
strengthens the assumption that tumour biology is involved. We
found no evidence that treatment is less active in the younger
women; rather we noticed a higher intensity of treatment
corresponding to treatment guidelines. The finding that the age
differences in survival are present primarily in stage I and II breast
cancer is thought-provoking.
The study population comprises a cohort of consecutive
women with primary breast cancer treated according to
national guidelines and international practice. The study base
is large including a considerable number of young women,
conferring a high statistical power for a study in this field. Data
were collected from well validated databases in two mainly
urban regions of Sweden, and very few women have been lost to
follow-up.
The major advantage of using relative survival in this type of
analysis is that information on cause of death is not required and
that it provides a measure of the excess mortality experienced by
patients diagnosed with cancer, irrespective of whether the excess
mortality is directly or indirectly attributable to the cancer.
When studying survival by age group in relative terms, one can
expect to see large differences as young women with clinically
detected tumours with generally more aggressive characteristics
stage by stage are being compared with a large group of women
with tumours mainly detected by screening mammography with
less aggressive characteristics. Still, this reflects that women ,35
years, with a normally long life expectancy, will have an absolute
risk of dying from their cancer of 25% in such a short follow-up
period as 5-year survival. Studies of long-term survival in young
women have also shown an increased mortality continuously for
up to 40 years after diagnosis [6,32]. This applies even when
breast cancer is diagnosed in a localized stage and in the absence
of a second primary breast cancer.
It is remarkable that there are such pronounced age-dependent
differences in survival in early breast cancer, which theoretically
should be curable. The most striking finding in this study is the
high relative excess risk in women ,35 years in stage I. Other
authors have also found the survival difference by age to be more
pronounced in early stages of disease [33,34]. Kroman et al found
the negative effect of young age to be significant only in women
with low risk disease who received no adjuvant chemotherapy. It
seems reasonable to search for the explanation for these differences
in tumour biology.
In our analyses of classical prognostic factors we found the same
pattern of more aggressive tumour characteristics in the youngest
women as previously published [8,11,12,13,14,15]. We lack data
on other reported important adverse prognostic factors in the
young such as high proliferation index [13,15,35], lymphovascular
invasion [8,15], and amplification of the Her-2 gene [14], as well
as on preoperative mammography findings with implications for
Table 3. Breast cancer survival by age and stage at diagnosis.
5-years survival Crude
Stage Age No. RSR 95% CI RER 95% CI
I
20–34 126 90.1 88.4–94.8 4.63 2.26–9.50
35–39 264 93.1 88.4–94.8 3.37 1.87–6.09
40–49 1836 97.1 96.0–98.0 1.40 0.92–2.14
50–69 7430 97.9 97.3–98.5 1.00 (ref.)
T=1–10 mm
20–34 36 90.9 67.4–97.9 6.70 1.49–30.2
35–39 78 95.1 84.8–98.6 3.48 0.93–13.0
40–49 623 99.2 97.6–100.0 0.61 0.18–2.13
50–69 2881 98.6 97.7–99.5 1.00 (ref.)
T=11–20 mm
20–34 90 90.1 80.0–95.2 3.88 1.73–8.72
35–39 186 92.3 86.6–95.7 3.11 1.62–6.01
40–49 1212 96.0 94.4–97.1 1.61 1.03–2.52
50–69 4542 97.5 96.6–98.2 1.00 (ref.)
IIA
20–34 146 77.0 68.4–83.5 3.04 2.05–4.50
35–39 262 92.1 87.6–95.1 1.05 0.64–1.74
40–49 1395 89.5 87.5–91.2 1.30 1.03–1.63
50–69 4179 91.9 90.8–92.9 1.00 (ref.)
IIB
20–34 106 61.7 50.7–71.0 1.78 1.25–2.52
35–39 184 78.0 70.7–83.8 0.97 0.68–1.37
40–49 826 84.6 81.7–87.2 0.64 0.51–0.81
50–69 1877 77.4 75.1–79.5 1.00 (ref.)
III
20–34 55 72.4 57.5–82.8 0.81 0.47–1.40
35–39 87 68.6 56.4–78.0 0.86 0.56–1.32
40–49 382 70.8 65.2–75.7 0.73 0.57–0.93
50–69 678 63.2 58.8–67.3 1.00 (ref.)
IV
20–34 15 00.0 - 0.67 0.33–1-37
35–39 25 26.8 9.8–47.4 0.80 0.48–1.33
40–49 95 27.1 16.8–38.3 0.74 0.55–1.00
50–69 271 23.7 17.8–30.1 1.00 (ref.)
Undefined
20–34 23 77.8 54.4–90.2 2.81 1.13–6-96
35–39 36 74.3 56.1–85.9 3.04 1.52–6.09
40–49 255 88.6 83.8–92.1 1.33 0.86–2.06
50–69 1464 91.3 89.4–92.9 1.00 (ref.)
Cumulative 5-year RSR and the estimated RER and 95% CI by stage at diagnosis
of women aged 20–69 years, diagnosed with primary breast cancer of all stages
between 1992 and 2005 (22 017 women).
doi:10.1371/journal.pone.0007695.t003
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of small tumours, 1–14 mm, showing a mammography pattern
with casting-type calcifications being more often present in young
women and independently predicting a poor survival [36].
After controlling for different histopathological features most
studies have shown young age to remain as a powerful predictor of
poor survival [8,37]. A possible development is that gene
expression profiling will be able to differentiate otherwise similar
breast cancers at the molecular level to find clues for the
explanation of this age effect [38,39]. Hereditary breast cancer
(e.g. BRCA1 and 2 mutations) is more frequent in young women
with breast cancer but this has not implied a worse survival in most
studies [40]. Other hypotheses to explain the remaining difference
in survival between age groups after corrections for tumour
characteristics are that the increased risk of local recurrence
associated with low age [41,42,43] leads to an increased risk of
breast cancer death [44] and that young women may differ from
older with respect to the treatment they are given and their
responsiveness to it, or presumably a combination of both
[45,46,47].
The young women inthe studyhad been given more intensive
treatment than the older women. However, judged against
current treatment guidelines, women in all age groups received
somewhat suboptimal treatment. Of the women operated with
breast conservation, 92–94% were given radiotherapy, while
65–73% of those with hormone receptor-positive tumours
Figure 1. Ten year cumulative survival in relation to expected survival (RSR) according to age and stage of women aged 20–69
years, diagnosed with primary breast cancer between 1992 and 2005 (22 017 women). Size of the groups as in Table 3. A: Stage I, B: Stage
IIa, C: Stage IIb, D: Stage III, E: Stage IV.
doi:10.1371/journal.pone.0007695.g001
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other population-based series [48,49]. The young women
should - according to the 1998 St Gallen guidelines [24] - have
received chemotherapy, but only 22% of the women ,35 years
with stage I disease with tumour size 1–10 mm and 39% with
tumour size 11–20 mm did so. The start of our study period
several years before the publication of the guidelines might
explain the low frequency of chemotherapy. Consequently,
there is room forfurther intensification of the treatment given to
all women.
With the results from this study based on a large, well-
validated data set, we can conclude that there are two major
factors explaining the worse prognosis in young women: late
presentation and a smaller, but highly significant component of
more aggressive tumour biology. The former underlines the
need for a raised awareness of breast cancer in society and
among doctors seeing younger patients for breast complaints.
The latter triggers several questions: can this aggressiveness be
counteracted by even more active treatment with modalities
available today, or are new modalities needed? Can we
understand the tumour behaviour in the younger women
better in order to aid management, e.g. by defining new
therapeutic targets? Will such knowledge further improve our
understanding of breast cancer biology overall? It would seem
that young women are a target group for intensified research of
the same importance as e.g. women with triple-negative breast
cancer.
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Table 4. The effect of prognostic factors on early breast cancer survival.
Age at diagnosis (years)
20–34 35–39 40–49 50–69
RER 95% CI RER 95% CI RER 95% CI
Total 1.76 1.37–2.26 0.98 0.75–1.27 0.76 0.65–0.89
Tumour size, 1–10 mm
1 6.20 2.19–17.53 2.67 0.97–7.33 1.48 0.66–3.29
Tumour size, 10–20 mm
1 2.93 1.83–4.69 1.27 0.79–2.04 1.19 0.91–1.54
Tumour size, 21+ mm
1 1.41 1.01–1.95 0.77 0.55–1.09 0.58 0.48–0.72
Lymph nodes, no
2 2.34 1.49–3.68 1.76 1.13–2.73 0.99 0.75–1.31
Lymph nodes, yes
2 1.66 1.22–2.26 0.78 0.56–1.09 0.71 0.59–0.86
ER+/PR+
3 2.27 1.47–3.50 1.15 0.77–1.70 0.80 0.62–1.02
ER2/PR2
3 1.32 0.91–1.92 1.00 0.67–1.49 0.92 0.73–1.16
1Adjusted for year at diagnosis, lymph node status and oncological treatment.
2Adjusted for year at diagnosis, tumour size and oncological treatment.
3Adjusted for year at diagnosis, stage and oncological treatment.
Effect on survival of women aged 20–69 years, diagnosed with primary breast cancer stage I-IIb between 1992 and 2005 (18 631 women), adjusted by year of diagnosis,
stage at diagnosis and oncological treatment (radiotherapy, chemotherapy, and endocrine therapy) and stratified on tumour characteristics.
doi:10.1371/journal.pone.0007695.t004
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Table 5. Treatments given to women with stage I breast cancer by age and tumour size.
Tumour size Total Mastectomy Chemotherapy
Total no.
with BCS
Radiotherapy
if BCS
Total no. with
hormone positive
tumour
Endocrine therapy
if hormone positive
tumour
No. No. (%) No. (%) No. No. (%) No. No. (%)
1–10 mm
20–34 years 36 16 (44.4) 8 (22.2) 20 18 (90.0) 22 15 (68.2)
35–39 years 78 22 (28.2) 9 (11.5) 56 49 (87.5) 48 24 (50.0)
40–49 years 623 115 (18.5) 26 (4.2) 503 473 (94.0) 365 161 (44.1)
50–69 years 2881 498 (17.3) 60 (2.1) 2363 2160 (91.4) 1744 951 (54.5)
11–20 mm
20–34 years 90 23 (25.8) 35 (38.9) 66 61 (92.4) 53 39 (73.6)
35–39 years 186 53 (28.7) 70 (37.6) 132 130 (98.5) 123 70 (56.9)
40–49 years 1212 277 (22.9) 212 (17.5) 926 879 (94.5) 859 538 (62.6)
50–69 years 4542 976 (21.5) 422 (9.3) 3542 3351 (94.6) 3296 2344 (71.1)
Proportions of women aged 20–69 years, diagnosed with primary breast cancer stage I between 1992 and 2005 (9656 women), receiving specific treatments, by tumour
size and age at diagnosis.
doi:10.1371/journal.pone.0007695.t005
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